Abstracts tagged "Lupus nephritis"

Abstract Number: 1243 • ACR Convergence 2023
Tubulointerstitial Inflammation Is Associated with End-Stage Renal Disease in Pediatric Lupus Nephritis: A Single Center Retrospective Cohort Study
Ryan Mitacek, Qiong Liu, Linda Wagner-Weiner, Shireen Hashmat and Anthony Chang, University of Chicago, Chicago, IL
Background/Purpose: Lupus nephritis (LN) is associated with significant morbidity and mortality. The 2018 International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification criteria and the NIH…
Abstract Number: 1506 • ACR Convergence 2023
Prescribing Patterns in Lupus Nephritis: Analyzing Time from Proteinuria to Prescription of ACE/ARB
JM JANSZ¹, WL GALLANTER¹, EM Adams², Nadera Sweiss³ and Huan Chang⁴, ¹University of Illinois at Chicago, Chicago, IL, ²Jesse Brown VA Medical Center, Chicago, IL, ³University of Illinois, Chicago, IL, ⁴University of Illinois at Chicago; Jesse Brown VA Medical Center, Chicago, IL
Background/Purpose: Black patients with lupus nephritis have worse renal outcomes compared with their White counterparts. Currently, there is a paucity of data evaluating the use…
Abstract Number: 2274 • ACR Convergence 2023
Lupus Low Disease Activity State as an Attainable Target in Lupus Nephritis Associated with Reduced Risk of Relapse
Chak Kwan Cheung¹, Chak Sing Lau² and Shirley Chiu Wai Chan³, ¹Divison of Rheumatology and Clinical Immunology, Queen Mary Hospital, Department of Medicine, the University of Hong Kong, Hong Kong, Hong Kong, ²University of Hong Kong, Division of Rheumatology & Clinical Immunology, Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ³Divison of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, the University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Lupus nephritis (LN) is a significant comorbidity affecting approximately up to 50-60% of patients with systemic lupus erythematosus (SLE). Complete renal response (CRR) and…
Abstract Number: 2535 • ACR Convergence 2023
Strategies to Embrace Living with Lupus Fearlessly (SELF): A Promising Digital Intervention for Lupus Self-Management
Katherine Carpenter¹, Melissa French², Sarah Gilman³, Sara Johnson⁴, Patricia Castle⁴, S. Sam Lim⁵, Charmayne Dunlop-Thomas⁵, Melicent Miller¹ and Mary Crimmings¹, ¹Lupus Foundation of America, Washington, DC, ²Lupus Foundation of America, Alexandria, VA, ³Wayfinder Health Strategies, Falls Church, VA, ⁴Pro-Change Behavior Systems, Inc., Narragansett, RI, ⁵Emory University, Atlanta, GA
Background/Purpose: The Lupus Foundation of America (LFA) has engaged in a 5-year cooperative agreement with the Centers for Disease Control and Prevention to implement a…
Abstract Number: 0556 • ACR Convergence 2023
Classical Complement Activation in Lupus Nephritis Correlates with Disease Biomarkers: Results from Two Observational Studies
Edmund Chang¹, Julian Low¹, Noosha Yousefpour¹, Min Bao¹, Jeannette Osterloh¹, Qing Chang¹, Dean Artis¹, Henk-Andre Kroon¹, Yaisa Andrews-Zwilling¹, Maria Dall'Era², Ted Yednock¹ and Ann Mongan¹, ¹Annexon Biosciences, Brisbane, CA, ²University of California San Francisco, San Francisco, CA
Background/Purpose: Lupus nephritis (LN) is an autoantibody-mediated disease that can activate C1q and the classical complement pathway. Pathogenic anti-C1q antibodies (PACAs) are often present, amplifying…
Abstract Number: 0888 • ACR Convergence 2023
Functionally Selective Immunomodulator Shows Robust Efficacy in Spontaneous Lupus Mouse Model
Helene ASNAGLI¹, Simon TESSIER¹, Martyn FOSTER², Sofie DENIES³, Eef HOEBEN⁴, Joël CROUZET¹ and Annegret VAN DER AA¹, ¹Ermium Therapeutics, Paris, France, ²Experimental Pathology Consultancy, Benfleet, United Kingdom, ³SD Analytics, Bellem, Belgium, ⁴2-Bridge, Zoersel, Belgium
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, heterogeneous autoimmune disease. There is still a high unmet need to improve current treatment options. Type 1…
Abstract Number: 1447 • ACR Convergence 2023
Increased Left Ventricular Mass Index in Systemic Lupus Erythematosus Patients with Lupus Nephritis Compared to Those Without Nephritis
Natalia Guajardo-Jauregui¹, Dionicio A. Galarza-Delgado², Iris Colunga², José Ramón Azpiri-López², Rosa Arvizu-Rivera³ and Jesus Alberto Cardenas-De la Garza⁴, ¹Hospital Universitario Dr. José Eleuterio González, Monterrey, Mexico, ²Hospital Universitario UANL, Monterrey, Mexico, ³Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico
Background/Purpose: Patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN) are at increased risk of cardiovascular (CV) morbidity and mortality, compared to those without…
Abstract Number: 1509 • ACR Convergence 2023
Calcineurin Inhibitors for Treatment of Lupus Nephritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Gabriel Figueroa-Parra¹, Maria Cuellar-Gutierrez¹, Mariana Gonzalez-Trevino¹, Larry J. Prokop², M. Hassan Murad³ and Ali Duarte-Garcia⁴, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Mayo Clinic Libraries, Mayo Clinic, Rochester, MN, ³Evidence-based Practice Center, Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Rochester, MN
Background/Purpose: The current recommendations for the treatment of LN consider as the standard of care (SoC) the use of MMF or CYC. Considering the expanding…
Abstract Number: 2275 • ACR Convergence 2023
Lupus Low Disease Activity State Ameliorates the Poor Prognosis in Lupus Nephritis Patients with anti-Sm Autoantibody
Chak Kwan Cheung¹, Chak Sing Lau² and Shirley Chiu Wai Chan³, ¹Divison of Rheumatology and Clinical Immunology, Queen Mary Hospital, Department of Medicine, the University of Hong Kong, Hong Kong, Hong Kong, ²University of Hong Kong, Division of Rheumatology & Clinical Immunology, Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ³Divison of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, the University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Anti-Sm autoantibody has been a known specific biomarker of systemic lupus erythematosus (SLE). There have been reports about its correlation with higher disease activity,…
Abstract Number: 2552 • ACR Convergence 2023
Inflammatory Fibrosis Precedes Loss of Kidney Function in Lupus Nephritis
Silvia Malvica¹, Paride Fenaroli², Serena Bagnasco¹, Jeff Hodgin³, Peter Izmirly⁴, H Michael Belmont⁵, Katie Preisinger⁴, Jill Buyon⁶, Larry Magder⁷, Michelle Petri⁸, the Accelerating Medicines Partnership in RA/SLE⁹, Avi Rosenberg¹ and Andrea Fava¹⁰, ¹Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, ²Nephrology and Dialysis Unit, Azienda USL - IRCCS Reggio Emilia, Reggio Emilia, Italy, ³University of Michigan, Ann Arbor, MI, ⁴New York University School of Medicine, New York, NY, ⁵NYU School of Medicine, New York, NY, ⁶Department of Medicine, NYU Grossman School of Medicine, New York, NY, ⁷University of Maryland, Baltimore, MD, ⁸Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁹Multiple, Multiple, ¹⁰Johns Hopkins University, Baltimore, MD
Background/Purpose: Interstitial fibrosis in lupus nephritis (LN) is often infiltrated by immune cells. However, this is typically regarded as nonspecific "scar reaction" rather than active…
Abstract Number: 005 • 2023 Pediatric Rheumatology Symposium
Real-World Application of the Pediatric Glucocorticoid Toxicity Index in Children with Lupus Nephritis: A Feasibility and Initial Validation Study
Emily Zhang¹, Gabrielle Alonzi¹, Madeline Hlobik¹, Esra Meidan¹, Mindy Lo¹, Olha Halyabar², Melissa Hazen¹, Ezra Cohen³, Lauren Henderson¹, Siobhan Case⁴, Margaret Chang¹, Camille Frank¹, Ankana Daga¹, Jonathan Hausmann⁵, Ahmad Bakhsh¹, Liyoung Kim¹, Daniel Ibanez¹, Holly Wobma¹, Mia Chandler⁶, Fatma Dedeoglu¹, Robert Sundel¹, Peter Nigrovic¹, Karen Costenbader⁷, Mary Beth Son¹ and Joyce Chang¹, ¹Boston Children's Hospital, Boston, MA, ²Children's Hospital/Boston Medical Center, Boston, MA, ³Boston Medical Center, Boston, MA, ⁴Brigham and Women's Hospital, Boston Children's Hospital, Boston, MA, ⁵Boston Children's Hospital / Massachusetts General Hospital, Boston, MA, ⁶Boston Children's Hospital; Brigham and Women's Hospital, Boston, MA, ⁷Brigham and Women's Hospital/ Harvard Medical School, Boston, MA
Background/Purpose: The morbidity of chronic glucocorticoid (GC) use is rarely captured as a standardized clinical outcome in pediatric rheumatic conditions. The newly developed pediatric glucocorticoid…
Abstract Number: 012 • 2023 Pediatric Rheumatology Symposium
Thrombotic Microangiopathic Changes in Kidney Biopsies of Childhood-Onset Systemic Lupus Erythematous Patients with and Without Severe Hematologic Disturbances
Cathy Tsin¹, Megan Troxell¹, Vivek Charu¹, Rufei Lu² and Joyce Hsu³, ¹Stanford University, Palo Alto, CA, ²UCSF, San Francisco, CA, ³Stanford Medicine, Children's Health, Palo Alto, CA
Background/Purpose: Outcomes for pediatric patients with lupus nephritis (LN) remain suboptimal. LN may present with thrombotic microangiopathy (TMA) seen on kidney biopsy. Childhood-onset SLE patients…
Abstract Number: 047 • 2023 Pediatric Rheumatology Symposium
Clinical Characteristics and Outcomes of North American Youth with Lupus Nephritis Requiring Dialysis Treated with Cyclophosphamide
Christine Wang¹, Rebecca Sadun², Wenru Zhou³, Kristen Miller³, Claire Palmer³, Stacy Ardoin⁴, Christine Bacha⁵, Emily Hause⁶, Joyce Hui-Yuen⁷, Nicole Ling⁸, Maria Pereira⁹, Meredith Riebschleger¹, Kelly Rouster-Stevens¹⁰, Aliese Sarkissian¹¹, Julia Shalen¹², William Soulsby¹³, Marinka Twilt¹⁴, Eveline Wu¹⁵, Laura Lewandowski¹⁶, Scott Wenderfer¹⁷ and Jennifer Cooper¹⁸, ¹University of Michigan, Ann Arbor, MI, ²Duke University, Durham, NC, ³University of Colorado, Denver, CO, ⁴Nationwide Children's Hospital, Columbus, OH, ⁵Akron Children's Hospital, Akron, OH, ⁶University of Minnesota, Minneapolis, MN, ⁷Cohen Children's Medical Center, Northwell Health, Lake Success, New York; Center for Autoimmune, Musculoskeletal, and Hematopoietic Diseases Research, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, ⁸UCSF, San Francisco, CA, ⁹Baylor College of Medicine, Houston, TX, ¹⁰Emory University/Children's Healthcare of Atlanta, Atlanta, GA, ¹¹UNC- Chapel Hill, Durham, NC, ¹²Johns Hopkins University, Baltimore, MD, ¹³University of California, San Francisco, San Francisco, CA, ¹⁴Alberta Children's Hospital, Calgary, AB, Canada, ¹⁵UNC Chapel Hill, Chapel Hill, NC, ¹⁶NIAMS, NIH, Bethesda, MD, ¹⁷British Columbia Children's Hospital, Vancouver, BC, Canada, ¹⁸University of Colorado/Children's Hospital Colorado, Denver, CO
Background/Purpose: Few studies have evaluated the clinical characteristics and outcomes of youth with lupus nephritis (LN) treated with cyclophosphamide (CYC) who initially required kidney replacement…
Abstract Number: 050 • 2023 Pediatric Rheumatology Symposium
Predictive Value of the 2019 EULAR/ACR SLE Criteria’s Extra-Renal Domains to Renal Response One Year After Treatment in a Pediatric Lupus Nephritis Cohort
Sara Patrizi¹, Megha Tandel², Derek Boothroyd² and Joyce Hsu¹, ¹Stanford Medicine, Children's Health, Palo Alto, CA, ²Quantitative Sciences Unit, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA
Background/Purpose: In 2019, new classification criteria for SLE were developed by the EULAR/ACR. Prior research in adult lupus cohorts found a positive correlation between high…
Abstract Number: 0336 • ACR Convergence 2022
Machine Learning Approach for the Prediction of Lupus Nephritis Renal Flares Using Polygenic Risk Score and Electronic Health Record
Yi-Ming Chen¹, Tzu-Hung Hsiao¹, Seng-Cho Chou² and Chi-Wei Chung², ¹Taichung Veterans General Hospital, Taichung, Taiwan, ²Department of Information Management, National Taiwan University, Taipei, Taiwan
Background/Purpose: Lupus nephritis (LN) flares are associated with risks of renal failure and mortality in patients with systemic lupus erythematous (SLE). It is critical to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].